Arch Biopartners Inc.
ARCH.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 114.30K | 114.30K | 198.50K | -65.90K | -180.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.30K | 114.30K | 198.50K | -65.90K | -180.20K |
| Cost of Revenue | 458.90K | 433.20K | 146.00K | 531.90K | 794.70K |
| Gross Profit | -344.70K | -319.00K | 52.40K | -597.90K | -974.90K |
| SG&A Expenses | 1.27M | 1.35M | 857.60K | 822.10K | 853.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.73M | 1.79M | 1.00M | 1.35M | 1.65M |
| Operating Income | -1.61M | -1.67M | -805.20K | -1.42M | -1.83M |
| Income Before Tax | -1.86M | -1.87M | -1.05M | -1.67M | -2.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.86 | -1.87 | -1.05 | -1.67 | -2.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.86M | -1.87M | -1.05M | -1.67M | -2.14M |
| EBIT | -1.61M | -1.67M | -805.20K | -1.42M | -1.83M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.03 | -0.03 | -0.02 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.02 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 264.66M | 263.19M | 262.02M | 257.29M | 253.93M |
| Average Diluted Shares Outstanding | 264.66M | 263.19M | 262.02M | 257.29M | 253.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |